Animal Cell Patents (Class 435/7.21)
  • Patent number: 11029318
    Abstract: In some embodiments, the present invention provides methods for treating pregnant patients at risk of adverse pregnancy outcome, including, in some embodiments, by measuring one or more of a level of iC3b, intact C3, and total C3.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: June 8, 2021
    Assignee: Kypha, Inc.
    Inventors: Nicholas Staten, Alfred Kim, Paul Olson
  • Patent number: 11022606
    Abstract: A cell information acquisition method may include: binding a binding substance to a receptor on a cell membrane surface of a cell, the binding substance being bindable to the receptor; permeabilizing a cell membrane of the cell after the binding; labeling a receptor in an intracellular area of the cell with a binding substance labeled with a first labeling substance after the permeabilizing; causing a specimen including the cell to flow through a flow path after the labeling; irradiating the cell included in the specimen flowing through the flow path with light; and acquiring a signal based on light generated from the first labeling substance in the cell irradiated with light.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 1, 2021
    Assignee: SYSMEX CORPORATION
    Inventors: Keiko Yoshikawa, Yuma Oka, Shingo Fujiyama
  • Patent number: 10983114
    Abstract: An improved method for the preparation of tetrameric antibody complexes directly on the surface of target entities in a sample is described. In particular, this method involves linking, in the sample, a first target entity with a second target entity in a sample using antibodies with specificity for the first and second target entities.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 20, 2021
    Assignee: STEMCELL Technologies Inc.
    Inventor: Andy Isamu Kokaji
  • Patent number: 10962555
    Abstract: The present invention provides for the first time the identification of fetal neural exosomal biomarkers isolated from maternal plasma useful in diagnosing fetal neurodevelopmental outcomes. The invention also provides the identification of neonatal neural exosomal biomarkers isolated from neonatal plasma useful in diagnosing neonatal neurodevelopmental outcomes The present invention therefore provides methods, kits and systems for diagnosing fetal neurodevelopmental outcomes, by examining relevant proteins and RNA in fetal neural exosomes isolated from a maternal plasma and neonatal neural exosomes isolated from neonatal plasma.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 30, 2021
    Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Laura Goetzl, Edward Goetzl
  • Patent number: 10953045
    Abstract: Immune-potentiating compositions include cells exhibiting enhanced antigen-presenting functions. The compositions are generally useful in facilitating the stimulation of host immune cell responses, including selective and targeted immune cell responses, and are particularly useful in the treatment and/or prophylaxis of cancers, tumors and pathogenic infections.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: March 23, 2021
    Assignee: CANCURE LIMITED
    Inventor: Stephen Ralph
  • Patent number: 10940187
    Abstract: Disclosed in this application are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of Schizophrenia or a Schizophreniform Disorder. Also disclosed is a method for treating an individual with Schizophrenia or a Schizophreniform Disorder using digestive enzymes and their derivatives to alleviate the symptoms of Schizophrenia or a Schizophreniform Disorder. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of Schizophrenia or a Schizophreniform Disorder.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: March 9, 2021
    Assignee: CUREMARK, LLC
    Inventors: Joan M. Fallon, Matthew Heil, James Szigethy, James Fallon
  • Patent number: 10930373
    Abstract: A system for analyzing biological data, comprising: a storage configured to store a plurality of data files containing biological data obtained from a plurality of devices; a server configured to: host a plurality of applications, each configured to be implemented on the server and to provide analysis, manipulation, comparison, visualization, or a combination thereof, of the biological data included in the data files, wherein the plurality of applications allow a user to analyze different data files related to the same sample and compare the results of the analysis.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: February 23, 2021
    Assignee: Life Technologies Corporation
    Inventors: Nivedita Sumi Majumdar, Harrison Leong, Shakila Pothini, David Hoard, Christopher Fong, Pratik Simon Soares, Salil Kumar, Thomas Wessel, Manjula Aliminati, Levente Egry
  • Patent number: 10920193
    Abstract: Described herein are chemically defined, adherent culture protocols for generating functional motor neurons characteristic of diverse hindbrain and spinal cord regions, with high efficiency.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: February 16, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ethan Scott Lippmann, Neha Sehgal, Randolph Scott Ashton
  • Patent number: 10914746
    Abstract: The invention relates to the field of the diagnosis and prognosis methods of molecular pathologies. In particular, the invention relates to methods for determining the diagnosis of an ectatic disease of the cornea in a subject, for determining the risk of developing an ectatic disease of the cornea in a subject, for determining the clinical outcome of a subject suffering from an ectatic disease of the cornea and for selecting a subject to be treated with a therapy for an ectatic disease of the cornea based on the determination of the expression levels of TLR2 and/or TLR4 markers. The invention also relates to the use of the TLR2 and/or TLR4 as diagnosis and prognosis markers for an ectatic disease of the cornea.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 9, 2021
    Assignees: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, SERVIZO GALEGO DE SAUDE (SERGAS)
    Inventors: María Isabel Lema Gesto, José Antonio Castillo Sánchez, Tomás Sobrino Moreiras, Francisco Campos Perez
  • Patent number: 10810904
    Abstract: Described herein are kits and methods for identifying the likelihood of having a food sensitivity or intolerance, and determining dietary modifications accordingly. For example, the likelihood of having sensitivities, intolerances or allergies to gluten, lactose, FODMAPs and others tested and calculated. Additionally, diet modifications can be determined according to the likelihood of particular sensitivities, and the effectiveness of diet modifications can be evaluated by monitoring of meals and subsequent symptoms, and evaluating the monitoring information. Through application of the methods herein, dietary intake and symptom data may be collected and aggregated to evaluate the effect or desirability of particular foods on a population of interest.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: October 20, 2020
    Assignees: CEDARS-SINAI MEDICAL CENTER, THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Brennan Spiegel, William D. Chey
  • Patent number: 10751384
    Abstract: The present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide corresponding to one or more of SEQ ID No(s) 1, 2, 3 or 4. The therapeutically effective amount of polypeptide may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation. Also disclosed are methods for treating at least one of diabetes, hyperglycemia, hypercholesterolemia, and hypertension in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide according to SEQ ID Nos. 1-4.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 25, 2020
    Assignee: IMAGINE PHARMA LLC
    Inventors: Ngoc Thai, Jonathan Pollett
  • Patent number: 10712339
    Abstract: A microfluidic device for more accurately modeling the in vitro environment in which cancer occurs is disclosed. The microfluidic device includes a surface defining one or more microfluidic channels, a first three dimensional scaffold comprising one or more cancer cells that is spatially separated from the one or more microfluidic channels, a second three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the first three dimensional scaffold, and that is spatially separated from the one or more microfluidic channels, and a third three dimensional scaffold, at least a portion of which is contacting and in fluid communication with the one or more microfluidic channels and the second three dimensional scaffold. The device can be used to assay anti-cancer agents, or as a system for modeling the growth, behavior, or metastasis and tumor formation of cancer cells.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 14, 2020
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Mehdi Nikkhah, Danh Truong
  • Patent number: 10669314
    Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-6, and provides an IL-6 binding polypeptide comprising the sequence EEX3X4AWX7EIH X11 LPNLX16X17X18QX20 X21AFIX25X26LX28X29. The present disclosure also relates to the use of such an IL-6 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: June 2, 2020
    Assignee: AFFIBODY AB
    Inventors: Fredrik Frejd, Elin Gunneriusson, Ingmarie Höidén-Guthenberg, Per-Ake Nygren, Susanne Klint, Feifan Yu
  • Patent number: 10668147
    Abstract: Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferably Pseudomonas exotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: June 2, 2020
    Assignees: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V., RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN
    Inventors: Christoph Stein, Radoslav Mladenov, Bernhard Stockmeyer, Stefan Barth, Lea Christin Schenke, Rainer Fischer
  • Patent number: 10588941
    Abstract: The invention provides compositions and methods for targeting CCR10 and/or the CCR10/ligand axis to modulate the immune response in a subject.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 17, 2020
    Assignee: THE PENN STATE RESEARCH FOUNDATION
    Inventors: Na Xiong, Mingcan Xia
  • Patent number: 10564150
    Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity which is achieved by adding a non-reducing sugar during incubation of the sample with the antigen.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 18, 2020
    Assignee: Cellestis Limited
    Inventors: Jeff Boyle, Ashley Knights, Carmen Munian
  • Patent number: 10564158
    Abstract: Methods and systems are provided for characterizing responses of a ligand-functionalized surface, which rely on dispensing a segmented liquid flow including liquid sequences, each including: an analyte segment including biomolecules of analyte; a spacer segment; and a wash segment including a washing liquid, whereby spacer segments separate wash segments from analyte segments in the dispensed segmented liquid flow. A measurement cycle is performed for each of the liquid sequences of the segmented liquid flow being dispensed. A measurement cycle includes: ejecting an analyte segment of each liquid sequence toward the ligand-functionalized surface and extracting, from each liquid sequence, a spacer segment succeeding the analyte segment as the latter is being ejected; ejecting a wash segment succeeding the extracted spacer segment in each liquid sequence to flush unbound and/or weakly bound biomolecules of analytes from the surface; and reading out a signal of bound biomolecules of analytes on the surface.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: February 18, 2020
    Assignee: International Business Machines Corporation
    Inventors: Moran Bercovici, Govind V. Kaigala, Xander F. van Kooten, Nadya Ostromohov, Federico Paratore
  • Patent number: 10556015
    Abstract: The invention provides compositions and methods for effective lysosomal targeting mediated by PCSK9. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Pompe Disease and Sanfilippo Syndrome Type B, and they may be used for targeting lysosomal enzymes to the various muscles of the human body.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: February 11, 2020
    Assignee: Criteo S.A.
    Inventors: Bohong Zhang, Michael F. Concino
  • Patent number: 10548941
    Abstract: The present invention provides a composition comprising a therapeutically effective amount of a polypeptide, peptide, or analog corresponding to one or more of SEQ ID NO(s) 1, 2, 3 or 4, and or more of a pharmaceutically acceptable carrier, pharmaceutically acceptable diluent, and/or pharmaceutically acceptable excipient. The polypeptide therapeutic of the present invention may be formulated for administration to a subject in need of treatment as an oral formulation, a parenteral formulation, a topical formulation, an aqueous formulation, a solid formulation, a lyophilized formulation, or a trans-dermal formulation. Also disclosed is a method for treating at least one of diabetes, and/or hyperglycemia, and/or hypercholesterolemia, and/or hypertension in a subject, comprising: administering to the subject a polypeptide of the invention or formulation of the invention.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: February 4, 2020
    Assignee: IMAGINE PHARMA
    Inventors: Ngoc Thai, Jonathan Pollett
  • Patent number: 10551392
    Abstract: The present invention, relates to the use of TFF3 in the diagnosis and detection of Barrett's Oesophagus using non-invasive, non-endoscopic methods.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: February 4, 2020
    Assignee: Covidien LP
    Inventors: Pierre Lao-Sirieix, Rebecca C. Fitzgerald
  • Patent number: 10545156
    Abstract: The invention relates to biomarkers associated with preterm delivery. More specifically, the invention provides methods of measuring biomarkers including but not limited to cytokines, cytokine receptors, cytokine receptor antagonists, chemokines, chemokine receptors, and/or chemokine receptor antagonists found in women that are at risk for preterm delivery. The diagnostic methods may be performed on whole blood.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 28, 2020
    Assignee: RPI Consulting, LLC
    Inventors: Ozlem Equils, Charles F. Simmons
  • Patent number: 10545081
    Abstract: The present invention relates to a method for the optical measurement of at least the stability and the aggregation of particles in a liquid sample which is located in a sample container, wherein the method comprises the following steps: irradiating the sample with light of at least one first wavelength in order to fluorescently excite the particles, irradiating the sample with light of at least one second wavelength in order to examine the scattering of the particles, measuring the fluorescence light which is emitted by the sample; and measuring the extinction light at the second wavelength, wherein the irradiated light of the second wavelength runs through the sample container, is reflected back, runs again through the sample container in the opposite direction and exits as extinction light, wherein the stability is determined based on the measured fluorescence light and the aggregation is measured based on the measured extinction light. The invention further relates to a corresponding apparatus.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: January 28, 2020
    Assignee: NANOTEMPER TECHNOLOGIES GMBH
    Inventors: Philipp Baaske, Stefan Duhr, Dennis Breitsprecher, Jonathan Derix
  • Patent number: 10526637
    Abstract: Methods for improving the specificity of assays for botulinum neurotoxins are described. Reporting constructs are provided that include cleavable linker sequence with genetically modified recognition and/or cleavage sites. These linker sequences act as a substrate for a botulinum neurotoxin, with cleavage of the reporting construct providing a detectable signal. When first and second neurotoxins have activity with the same substrate protein, mutation and/or deletion of a recognition and/or cleavage site associated with the second neurotoxin improves the specificity of the detectable signal for the first neurotoxin.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 7, 2020
    Assignee: BIOMADISON, INC.
    Inventors: Robert D. Fish, Min Dong
  • Patent number: 10473671
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 12, 2019
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Patent number: 10458902
    Abstract: Disclosed is an analysis component and associated systems and methods. The analysis component can be used with an electronic device equipped with a detector for detecting light. The component comprises: a sample holder for holding the sample; a detector site at which a detector, or a detector portion of the electronic device, is to be positioned to detect light reflecting off the sample; and a structural component spacing the sample holder from the detector site by a predetermined distance; wherein the lysis component is configured to allow light from a light source to illuminate the sample such that light reflected by the sample can be received by the detector for analyzing the sample. An associated system comprises the analysis component and a detector for detecting light reflected off the sample.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: October 29, 2019
    Assignee: Australian Sensing and Indentification Systems Pty. Ltd.
    Inventors: Sandra Ast, John Canning
  • Patent number: 10450607
    Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: October 22, 2019
    Assignee: 10X GENOMICS, INC.
    Inventors: Benjamin Hindson, Christopher Hindson, Michael Schnall-Levin, Kevin Ness, Mirna Jarosz, Serge Saxonov
  • Patent number: 10420503
    Abstract: A method of measuring efficacy of treatment of multiple sclerosis (MS) in an animal in a vivarium is described. Animal activity data is collected at multiple times during the night. Sequential time regions of the night are identified as high-activity, activity-drop, or low-activity regions. Embodiments are described to quantify a drop, during the night, of an animal's activity level. These quantified activity-drop scalars for consecutive nights are accumulated in an animal health dataset. This dataset is compared to healthy animals or a standard of care to determine efficacy. One embodiment quantifies an activity-drop by fitting straight-line curves through the data in the three nightly regions. Another embodiment uses a Fourier transform on a circle and a linear combination. Another embodiment compares areas under data curves in the regions. Animals may be housed in cages with other animals.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 24, 2019
    Assignee: Vium, Inc.
    Inventors: Daniel J. Ford, Laura Schaevitz
  • Patent number: 10418126
    Abstract: Herein is reported a method for selecting or deselecting an antibody comprising a) determining for each Asp and Asn residue in an antibody Fv region the conformational flexibility of the C?-atom using a homology model ensemble, b) determining for each Asp and Asn residue in an antibody Fv region the size of the amino acid residue C-terminal to the Asp or Asn residue, and c) selecting an antibody in which the C?-atom is conformationally inflexible and/or the Asp or Asn has a big C-terminal amino acid residue, or deselecting an antibody in which the C?-atom has a moderate to high conformational flexibility and/or the Asp or Asn has a small C-terminal amino acid residue.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: September 17, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hubert Kettenberger, Stefan Klostermann, Florian Lipsmeier, Apollon Papadimitriou, Jasmin Sydow-Andersen
  • Patent number: 10398710
    Abstract: The present invention is directed to a method for screening a regulator of mitochondrial fission using a cell treated to a protopanaxadiol (PPD)-type ginsenoside compound, a composition therefor, and a kit comprising the composition. As the use of the method for screening the regulator of mitochondrial fission of the present invention enables effective discovery of a formulation capable of preventing, improving, or treating a mitochondria-related disease, the method will be widely used for the development of a therapeutic agent for the mitochondria-related disease.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: September 3, 2019
    Assignee: INTELLIGENT SYNTHETIC BIOLOGY CENTER
    Inventors: Chul Hee Choi, Eun Soo Kim, Kyung Sun Choi, Seung Wook Ryu, Jin Gang Hou
  • Patent number: 10393750
    Abstract: One or more cells are labeled with minor stable isotopes, characterized, and preserved for subsequent use as a bio-specimen reference standard. The one or more cells are grown in culture media supplied with minor stable isotopes in concentrations substantially different from normally occurring concentrations, thereby supplanting major stable isotopes that would normally be incorporated into the proteins of the cells. The proteins of the cells are thus labeled by the minor stable isotopes and can be used in protcomic characterization of the cells. The cells are preserved by fixation as a reference standard. Cells of the reference standard are mixed with the sample and subject to mass spectrometry evaluation, whereby the labeled proteins of the reference standard can be used in determining the proteome of the sample.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: August 27, 2019
    Assignee: BIOPROXIMITY, LLC
    Inventor: Brian M. Balgley
  • Patent number: 10368791
    Abstract: Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: August 6, 2019
    Assignee: Medtronic Adrian Luxembourg S.a.r.l.
    Inventors: Ayala Hezi-Yamit, Rudy Beasley, Susan Thornton Edwards, Lori Garcia, Michele Lee Silver, Christopher W. Storment, Carol M. Sullivan, Joseph A. Traina, Stefan Stoyanov Tunev
  • Patent number: 10351914
    Abstract: Biomarkers and driver mutations for diagnosis and prognosis of Pin 1-associated diseases are disclosed. In one embodiment, the methods for diagnosis of Pin 1-associated diseases may include detecting the level of Pin1 to stage abnormal cell growth, such as breast or prostate cancer. In another embodiment, the methods include evaluating the efficacy of a treatment of abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the methods include using driver mutations to determine the pharmacogenetics of abnormal cell growth, such as cancer. In the present disclosure, elevated active monomeric Pin1 levels may be detected by Pin1 biomarkers, which may include Pin1 Q33K or E100D driver mutations, Pin1 protein or transcript overexpression, dephosphorylation of Pin1 on Ser71, dephosphorylation of S16, phosphorylation of S65, phosphorylation of S138, deacetylation of Pin1 on K13 and deacetylation of K46, and/or desumoylation of Pin1 on K6 and desumolation of K63, among others.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: July 16, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou, Shuo Wei
  • Patent number: 10344052
    Abstract: Provided are peptides, fusion proteins which include the peptide sequences, compositions comprising such peptides and fusion proteins, and methods for making and using the compositions. The peptides are characterized as being able to selectively bind to components of the endothelial compartment that are exposed during the period between 1 and 7 days after androgen deprivation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 9, 2019
    Assignee: Health Research, Inc.
    Inventors: Gary Smith, Ryan Willard
  • Patent number: 10324088
    Abstract: The present invention provides methods for predicting whether an individual having inflammatory bowel disease (IBD) is likely to respond to vedolizumab treatment. Also provided are methods for predicting whether an individual with IBD such as Crohn's disease or ulcerative colitis will develop autoantibodies against vedolizumab. The present invention also provides a treatment regimen for an IBD patient which includes measuring the level of one or more predictive markers of response to vedolizumab prior to administering the anti-?4?7 integrin drug.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: June 18, 2019
    Assignee: NESTEC S.A.
    Inventors: Sharat Singh, Anjali Jain, Venkateswarlu Kondragunta
  • Patent number: 10234465
    Abstract: Methods for identifying subjects as candidates for embryo implantation are provided. In some embodiments, the methods include providing a sample of endometrium isolated from a subject during the second half of the subject's menstrual cycle and determining whether the subject is a candidate based on the expression of BCL6 in the sample. Also provided are methods for identifying an increased risk for implantation failure subsequent to in vitro fertilization (IVF) and/or frozen embryo transfer (FET), methods for detecting endometrial receptivity, methods for facilitating diagnoses of infertility, methods for increasing the likelihood of embryo implantation, methods for detecting the presence of endometriosis, and methods for managing treatment of subjects with potential endometriosis, subfertility, or both.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: March 19, 2019
    Assignees: The University of North Carolina at Chapel Hill, Greenville Health Systems
    Inventors: Steven Young, Bruce Lessey
  • Patent number: 10220002
    Abstract: Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: March 5, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Joseph A. Vetro, Sam D. Sanderson
  • Patent number: 10215767
    Abstract: The present invention provides a method of detecting platelet activation in a patient, the method comprising the steps of a) obtaining a blood sample from a patient suspected of having heparin-induced thrombocytopenia (HIT); b) incubating an effective amount of platelet factor 4 (PF4) with a sample of platelets to yield a sample of PF4-treated platelets; c) contacting the patient blood sample with the PF4-treated platelets; and d) measuring the extent of platelet activation, wherein an increase in platelet activation compared with results obtained using a normal blood sample is indicative of the patient having HIT.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: February 26, 2019
    Assignee: Versiti Blood Research Institute Foundation, Inc.
    Inventors: Richard H. Aster, Daniel W. Bougie, Curtis Gerald Jones, Anand Padmanabhan
  • Patent number: 10195313
    Abstract: Patterned hydrogel arrays and methods of preparing patterned hydrogel arrays are disclosed. Advantageously, the methods used to prepare the patterned hydrogel arrays allow for controlling individual hydrogel spot conditions such as hydrogel spot modulus, hydrogel spot ligand identity and hydrogel spot ligand density, which allows for preparing a wide range of hydrogel spots in a single array format. Patterned hydrogel arrays can also be formed to include hydrogel-free pools surrounded by hydrogel. Additionally, the patterned hydrogel arrays of the present disclosure support the culture of a range of cell types. The patterned hydrogel arrays offer the ability to rapidly screen substrate components for influencing cell attachment, spreading, proliferation, migration, and differentiation.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: February 5, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William L. Murphy, Ngoc Nhi Thi Le, Stefan Zorn, Michael P. Schwartz, Eric Huy Dang Nguyen
  • Patent number: 10197561
    Abstract: The invention is directed to a method for detecting a target moiety in a sample of biological specimens by: a) providing at least one conjugate with the general formula (I) Xn—P—Ym, with X is an detection moiety, P an enzymatically degradable spacer and Y an antigen recognizing moiety and n, m are integers between 1 and 100 and wherein X and Y are covalently bound to P; b) contacting the sample of biological specimens with at least one conjugate, thereby labeling the target moiety recognized by the antigen recognizing moiety Y; c) detecting the target moiety labeled with the conjugate with the detecting moiety X; and d) enzymatically degrading spacer P, thereby cleaving the detection moiety X from the conjugate. The method is useful to identify target moieties on the biological specimens. The biological specimens detected by the conjugate can be subsequently removed from the sample.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: February 5, 2019
    Assignee: Miltenyi Biotec, GmbH
    Inventors: Christian Dose, Jennifer Brieden, Stefan Miltenyi, Thomas Rockel, Veronika Gann
  • Patent number: 10197563
    Abstract: Disclosed is a three-dimensional (3-D) in vitro model for studying and subsequently treating cancer dormancy. The model is specifically useful in studying breast cancer and may be used for drug discovery because it maintains the breast cancer cells in a dormant state, unlike conventional two-dimensional (2-D) tissue culture plastic (TCP). Tumor-forming breast cancers cells were seeded on the 3-D model scaffolds and remained viable without proliferation. They also express stem cell markers typical for dormant cells. Dormant breast cancer cells also maintain their phenotype when seeded on the 3-D model unlike conventional 2-D models. The 3-D model includes a fibrous polycaprolactone with 30 wt. % hydroxyapatite. The 3-D model mimics the structure of bone tissue.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 5, 2019
    Assignees: New Jersey Institute of Technology, Rutgers, The State University of New Jersry
    Inventors: Treena Lynne Arinzeh, Pranela Rameshwar, Khadidiatou T. Guiro
  • Patent number: 10184950
    Abstract: Methods of testing HIV viral load are described. The methods comprise detecting HIV viral RNA in a sample of leukocyte-depleted blood. Such methods can be carried out on low-volume samples obtained without the need for venipuncture or a centrifuge. The methods are particularly suited for HIV viral load testing in resource-limited settings. Methods for monitoring HIV infection are also described, as well as kits for carrying out the methods.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 22, 2019
    Assignee: DIAGNOSTICS FOR THE REAL WORLD, LTD
    Inventor: Jean-Pierre Allain
  • Patent number: 10174275
    Abstract: The present invention provides a microcapsule comprising a shell and a core. The core comprises at least one active ingredient and at least one surface-modified disintegrant.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: January 8, 2019
    Assignee: FOLLMANN GMBH & CO. KG
    Inventor: Klaus Last
  • Patent number: 10160948
    Abstract: The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: December 25, 2018
    Assignee: ABT HOLDING COMPANY
    Inventors: Henry E. Young, Paul A. Lucas
  • Patent number: 10127433
    Abstract: Embodiments disclosed herein are directed, among other things, to imaging systems, methods, and apparatuses for automatically identifying fields of view (FOVs) for regions in an image encompassing tumor are disclosed. In embodiments and in further aspects of the present invention, a computer-implemented method is disclosed for a tumor region based immune score computation. The method, in accordance with the present invention, involves identifying regions, for example, tumor areas or regions around a tumor area, partitioning a whole slide image or portion of a whole slide image into multiple regions related to the tumor, selecting FOVs within each identified region, and computing a number of cells present in each FOV. An immune score and/or immune-related score may be generated based on the cells counted in each FOV.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: November 13, 2018
    Assignee: VENTANA MEDICAL SYSTEMS, INC.
    Inventors: Paolo Ascierto, Michael Barnes, Christophe Chefd'hotel, Ting Chen, Alisa Tubbs
  • Patent number: 10114012
    Abstract: Methods for detecting nonactivated basophils in a whole blood sample obtained from a normal healthy subject, methods for determining a subject's susceptibility to an allergic reaction to an allergen, where the subject has no known allergy to the allergen, methods for measuring a response to challenge with a potential allergen in a whole blood sample obtained from a subject with known allergic reactivity to allergens other than the potential allergen; and an in vitro system for reliable detection or quantification of a specific white blood cell population in a whole blood sample are described.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: October 30, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Yael Gernez, Leonore A. Herzenberg, Kari Nadeau, Rabindra Tirouvanziam
  • Patent number: 10114923
    Abstract: A method comprises obtaining results of metagenomics sequencing performed on biological samples from respective sample sources, generating hit abundance score vectors for respective ones of the samples based at least in part on the metagenomics sequencing results, obtaining epidemiological data relating to at least one of a disease, infection or contamination characterized by one or more of the hit abundance score vectors, and generating patient comparative indexes based at least in part on the epidemiological data. The method further comprises obtaining one or more Big Data profiles relating to one or more of the hit abundance score vectors and one or more of the comparative indexes, and providing surveillance functionality utilizing a combination of the hit abundance score vectors and the patient comparative indexes based at least in part on information derived from the one or more Big Data profiles.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: October 30, 2018
    Assignee: EMC IP Holding Company LLC
    Inventors: Patricia Gomes Soares Florissi, Michal Ziv Ukelson, Ran Dach, Arnon Benshahar
  • Patent number: 10040067
    Abstract: The disclosure relates to a method and a system for the isolation of picoliter droplets from a continuous stream of carrier fluid in a microfluidic system. In particular the disclosure relates to a system that comprises a sorter, a detector and a collector. The sorter serves for a selection of picoliter droplets with a desired content based upon an optical signal obtained from the picoliter droplets. The selected picoliter droplets are guided towards the detector that comprises a detection channel that is arranged perpendicular to a light beam. By means of a photodetector that is aligned with the optical axis of the light beam the passage of the picoliter droplets can be detected. The collector comprises multiple wells and the detection of the passage of the picoliter droplets results in a relative movement of the detector and a collector such that the picoliter droplet is isolated by depositing it into one of said wells.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: August 7, 2018
    Assignee: LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE—HANS-KNÖLL-INSTITUT
    Inventors: Miguel Tovar, Emerson Zang, Thomas Weber
  • Patent number: 10018622
    Abstract: Methods and kits for identifying abnormal urinary system cells in a sample, by contacting the cells or the sample containing same with a combination of an extract from a Ficus plant, or one or more components thereof, an acidic dye and a basic dye.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: July 10, 2018
    Assignee: ZETIQ TECHNOLOGIES LTD.
    Inventors: Pavel Idelevich, Adi Elkeles, Dov Terkieltaub, Ami Eyal, Dan Jacob Gelvan
  • Patent number: 10012658
    Abstract: A method for diagnosis of HIT (Heparin-induced thrombocytopenia) in a patient's serum or plasma sample and a system comprising kits for performing the method are provided, where the method involves incubating a patient's sample with and without heparin and normal control sample with and without heparin with a platelet-rich plasma (PRP) of an individual not having a platelet disorder and then incubating an aliquot of each sample with a first label for both heparin activated and non-heparin activated platelets and a second label for platelets activated by the heparin-immune complex formed in the patient sample. HIT is diagnosed when the difference between the amount of activated platelets from the patient's sample with and without heparin is substantially larger than the difference between the normal control sample with and without heparin.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: July 3, 2018
    Assignee: EMOSIS
    Inventor: Aaron Tomer
  • Patent number: 10006903
    Abstract: The present invention relates to an in vitro use of a number of IL-4 and/or IL-13 secreting T-cells as a biomarker for diagnosing and/or monitoring an IgE-dependent allergic disease.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: June 26, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PIERRE ET MARIE CURIE—PARIS 6
    Inventors: Jocelyne Just, Benedicte Michaud, Jean-Francois Bach, Lucienne Chatenoud